Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference

DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 12^th at 11:45 AM ET in New York, NY. 

A live webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion - the root causes of many serious or currently untreatable amyloid and inflammatory diseases - Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies.  Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and inflammatory diseases, including psoriasis (PRX003), and TTR amyloidosis (PRX004). For more information, please visit the company's web site at www.prothena.com.

For more information, please visit the company's web site at www.prothena.com.

Contacts

Investors: Tran Nguyen, CFO
650-837-8535, [email protected]

Media: Ellen Rose
650-922-2405, [email protected]

You May Also Be Interested In

• Cantor Fitzgerald Starts Enhanced Group Inc. (ENHA) at Overweight
• An International Event for the 400th Birth Anniversary of Bada Shanren held in Qingyunpu District, China's Jiangxi
• Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa